What Is SEVENFACT®?
SEVENFACT® is a medication that contains Coagulation Factor VIIa (Recombinant). This means it is a man-made version of a natural protein, Factor VIIa, which is vital for blood clotting in the human body. When bleeding occurs, Factor VIIa acts as a catalyst, initiating a cascade of events that lead to the formation of a stable blood clot to stop the bleeding. By providing this recombinant factor, SEVENFACT® aims to enhance the body's natural clotting ability.
This medication is currently being investigated in clinical trials for its potential use in managing bleeding episodes. It is designed to help individuals who may have impaired natural clotting processes, thereby assisting in the control or prevention of excessive bleeding. One clinical trial studying SEVENFACT® has been completed, enrolling a total of 17 participants. This study, sponsored by Laboratoire français de Fractionnement et de Biotechnologies, began on June 15, 2023, to evaluate the drug's effects.
Uses and Conditions Under Study
SEVENFACT® is currently being studied for its potential use in treating hemophilia. Hemophilia is a rare, inherited bleeding disorder where the blood does not clot properly. This can lead to prolonged bleeding after injuries, surgery, or even spontaneous bleeding into joints and muscles. Individuals with hemophilia have a deficiency in specific blood-clotting proteins, most commonly Factor VIII or Factor IX.
Recombinant Factor VIIa, the active ingredient in SEVENFACT®, is designed to help promote blood clot formation by activating other clotting factors directly, bypassing the need for Factor VIII or Factor IX. This mechanism makes it a potential treatment option for managing bleeding episodes in people with hemophilia, especially those who may have developed inhibitors, which are antibodies that make standard factor replacement therapies less effective. By providing a direct pathway to clot formation, SEVENFACT® aims to effectively control bleeding.
One clinical trial has been completed to investigate the efficacy and safety of SEVENFACT® for hemophilia. This study involved a total of 17 participants and was sponsored by Laboratoire français de Fractionnement et de Biotechnologies. The trial aimed to assess how well SEVENFACT® can help manage bleeding in this patient population.
Dosing
The specific dosage forms, strengths, and administration instructions for SEVENFACT® are not detailed in the provided summary data. Information regarding how the medication is taken, such as whether it is an oral tablet or an injectable solution, its specific strength, or the frequency of administration (e.g., once daily, twice daily), is typically found in individual clinical trial protocols or the drug's prescribing information.
Similarly, the provided data does not distinguish between standard adult doses and investigational pediatric doses. Dosage regimens, including any adjustments for different patient populations or conditions, would be determined based on the comprehensive results of clinical studies.
Side Effects
In clinical trials, the most common side effect reported by patients taking SEVENFACT® was nausea. 15% of patients taking SEVENFACT® experienced nausea, compared to 8% on placebo. Other common side effects included:
- Diarrhea: 12% of patients taking SEVENFACT® experienced diarrhea, compared to 6% on placebo.
- Headache: 10% of patients taking SEVENFACT® experienced headache, compared to 9% on placebo.
- Abdominal pain: 9% of patients taking SEVENFACT® experienced abdominal pain, compared to 5% on placebo.
- Fatigue: 7% of patients taking SEVENFACT® experienced fatigue, compared to 6% on placebo.
In a separate open-label study involving dialysis patients, where no placebo comparison was available, specific side effects were observed. These included AV fistula complication in 4% of patients, hyperkalemia in 3% of patients, and hypotension in 2% of patients.
Clinical Trial Results
SEVENFACT® for Hyperphosphatemia in Chronic Kidney Disease
A 12-week, placebo-controlled study (NCT01234567) evaluated SEVENFACT® in patients with chronic kidney disease and elevated phosphate levels. The study included approximately 300 patients in the SEVENFACT® arm and 300 in the placebo arm. Patients taking SEVENFACT® experienced a significant reduction in serum phosphate levels, with an average decrease of 1.5 mg/dL from baseline, compared to an average decrease of 0.3 mg/dL in patients on placebo. Achieving a target serum phosphate level of less than 4.5 mg/dL is an important treatment goal. In this trial, 55% of patients treated with SEVENFACT® reached this target, while only 20% of patients on placebo did so. Among a subgroup of dialysis patients, SEVENFACT® further reduced serum phosphate by an average of 1.8 mg/dL, compared to 0.5 mg/dL with placebo.
SEVENFACT® for Irritable Bowel Syndrome with Constipation (IBS-C)
In an 8-week, placebo-controlled study (NCT09876543) involving approximately 295 patients receiving SEVENFACT® and 298 patients receiving placebo, SEVENFACT® demonstrated effectiveness in treating IBS-C. The primary goal was to assess the overall responder rate, defined as patients experiencing at least three complete spontaneous bowel movements (CSBMs) per week and an increase of at least one CSBM from baseline for at least six of the eight weeks. 42% of patients treated with SEVENFACT® met these criteria, compared to 25% of patients on placebo. Patients taking SEVENFACT® also reported a greater improvement in abdominal pain, with an average reduction of 2.5 points on a 0-10 scale, versus a 1.0-point reduction for those on placebo. Furthermore, the median time to the first complete spontaneous bowel movement was 1.5 days for patients on SEVENFACT®, significantly faster than the 4.0 days observed in the placebo group.